MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.97−0.08 (-3.90%)
Close on Nov 18, 2026Market cap $125.49MP/E –Yield –
MacroGenics net income
Net income is the profit left for shareholders after every expense, interest and tax.
MacroGenics's net income for the twelve months ending Jun 30, 2026 was -$14.59M. For fiscal 2025 it was -$74.62M. The highest annual figure on record is $8.36M in fiscal 2012.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$74.62M | – |
| FY2024 | Dec 31, 2024 | -$66.97M | – |
| FY2023 | Dec 31, 2023 | -$9.06M | – |
| FY2022 | Dec 31, 2022 | -$119.76M | – |
| FY2021 | Dec 31, 2021 | -$202.12M | – |
| FY2020 | Dec 31, 2020 | -$129.74M | – |
| FY2019 | Dec 31, 2019 | -$151.81M | – |
| FY2018 | Dec 31, 2018 | -$171.45M | – |
| FY2017 | Dec 31, 2017 | -$19.63M | – |
| FY2016 | Dec 31, 2016 | -$58.53M | – |
| FY2015 | Dec 31, 2015 | -$20.14M | – |
| FY2014 | Dec 31, 2014 | -$38.31M | – |
| FY2013 | Dec 31, 2013 | -$261.00K | -103.1% |
| FY2012 | Dec 31, 2012 | $8.36M | +24.5% |
| FY2011 | Dec 31, 2011 | $6.72M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$36.77M | – |
| Q4 FY2025 | Dec 31, 2025 | -$14.16M | – |
| Q3 FY2025 | Sep 30, 2025 | $16.82M | -70.1% |
| Q2 FY2025 | Jun 30, 2025 | -$36.25M | – |
| Q1 FY2025 | Mar 31, 2025 | -$41.04M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.42M | – |
| Q3 FY2024 | Sep 30, 2024 | $56.31M | +220.8% |
| Q2 FY2024 | Jun 30, 2024 | -$55.66M | -196.9% |
| Q1 FY2024 | Mar 31, 2024 | -$52.19M | – |
| Q4 FY2023 | Dec 31, 2023 | -$46.07M | -459.9% |
| Q3 FY2023 | Sep 30, 2023 | $17.55M | – |
| Q2 FY2023 | Jun 30, 2023 | $57.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$38.01M | – |
| Q4 FY2022 | Dec 31, 2022 | $12.80M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$41.30M | – |
| Q1 FY2022 | Mar 31, 2022 | -$66.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$58.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$52.89M | – |
| Q2 FY2021 | Jun 30, 2021 | -$39.94M | – |
| Q1 FY2021 | Mar 31, 2021 | -$51.27M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.09M | – |
| Q3 FY2020 | Sep 30, 2020 | -$36.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$46.89M | – |
| Q1 FY2020 | Mar 31, 2020 | -$44.72M | – |
| Q4 FY2019 | Dec 31, 2019 | -$30.40M | – |
| Q3 FY2019 | Sep 30, 2019 | -$44.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$31.77M | – |
| Q1 FY2019 | Mar 31, 2019 | -$45.02M | – |
| Q4 FY2018 | Dec 31, 2018 | -$44.64M | -142.2% |
| Q3 FY2018 | Sep 30, 2018 | -$34.03M | – |
| Q2 FY2018 | Jun 30, 2018 | -$43.24M | – |
| Q1 FY2018 | Mar 31, 2018 | -$49.54M | – |
| Q4 FY2017 | Dec 31, 2017 | $105.73M | – |
| Q3 FY2017 | Sep 30, 2017 | -$47.04M | – |
| Q2 FY2017 | Jun 30, 2017 | -$40.65M | – |
| Q1 FY2017 | Mar 31, 2017 | -$37.66M | – |
| Q4 FY2016 | Dec 31, 2016 | -$34.78M | – |
| Q3 FY2016 | Sep 30, 2016 | -$33.85M | – |
See a number that looks wrong?